Selected study cohort characteristics | Double Diabetes | |
---|---|---|
No (n = 45) | Yes (n = 62) | |
Age at clinic (years) | 24.0 (21.5–38.5) | 37.0 (24.0-51.3)* |
Age at diagnosis (years) | 18.0 (11.0-25.5) | 16.5 (9.0–29.0) |
Diabetes duration (years) | 9.0 (2.0–17.0) | 14.0 (8.8–26.5)* |
Female [n (%)] | 22 (49) | 29 (47) |
Body weight (kg) | 64.0 (61.1–74.3) | 80.5 (73.1–94.2)* |
BMI (kg/m2) | 22.9 (20.7–24.3) | 29.1 (25.3–34.1)* |
HbA1c (mmol/mol) | 63.0 (53.5–73.0) | 72.5 (66.8–87.0)* |
Total Insulin dose (units) | 42.0 (30.8–54.5) | 57.0 (42.3–80.5)* |
Insulin dose (unit/kg/day) | 0.65 (0.45–0.82) | 0.71 (0.56–0.93)* |
Total Cholesterol (mmol/L) | 4.1 (3.5–4.9) | 4.4 (3.6-5.0) |
Triglyceride (mmol/L) | 0.9 (0.6–1.3) | 1.3 (0.9–1.8)* |
HDL Cholesterol (mmol/L) | 1.6 (1.3–1.9) | 1.4 (1.1–1.7)* |
LDL Cholesterol (mmol/L) | 2.0 (1.6–2.5) | 2.5 (1.8–3.2) |
Hypertension, [n (%)] | 0 (0) | 20 (32)* |
Statins [n (%)] | 10 (22) | 23 (37) |
ACEI/ARB [n (%)] | 3 (7) | 19 (31)* |
Metformin [n (%)] | 5 (11) | 9 (15) |
Microalbuminuria, [n (%)] | 2 (4.4) | 15 (24)* |
eGDR | 8.9 (8.5–10.0) | 6.1 (4.5–7.3)* |